Novel Insulin Sensitizer Modulates Nutrient Sensing Pathways and Maintains β-Cell Phenotype in Human Islets

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Rohatgi, Nidhi ^a   Aly, Haytham ^a   Marshall, Connie A ^a   McDonald, William G ^b   Kletzien, Rolf F ^b   Colca, Jerry R ^b   McDaniel, Michael L ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b Metabolic Solutions Development Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; BETA CATENIN; GLITAZONE DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; INSULIN SENSITIZING AGENT; LITHIUM CHLORIDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MSDC 0160; NEW DRUG; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PNU 91325; PROTEIN KINASE B; SOMATOMEDIN C; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG; WNT PROTEIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; INSULIN; MSDC-0160; MTOR PROTEIN, HUMAN; PROPROTEIN CONVERTASE 2; PYRIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAX GENE; BCL2 GENE; BCLXL GENE; CELL EXPANSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MODEL; DNA SYNTHESIS; DOWN REGULATION; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; EX VIVO STUDY; EXPERIMENTAL DIABETES MELLITUS; EXPERIMENTAL MOUSE; GENE; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN GENE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; MALE; NKX2.2 GENE; NKX6.1 GENE; NONHUMAN; PANCREAS ISLET BETA CELL; PDX1 GENE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; APOPTOSIS; CELL CULTURE; CELL NUCLEUS; DNA REPLICATION; DRUG EFFECTS; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; PROTEIN TRANSPORT; SECRETION (PROCESS); SPRAGUE DAWLEY RAT; TISSUE CULTURE TECHNIQUE;

ADENYLATE KINASE; ANIMALS; APOPTOSIS; BETA CATENIN; CELL NUCLEUS; CELLS, CULTURED; DNA REPLICATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; INSULIN-SECRETING CELLS; MALE; MAP KINASE SIGNALING SYSTEM; PHENOTYPE; PHOSPHORYLATION; PROPROTEIN CONVERTASE 2; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TISSUE CULTURE TECHNIQUES; TOR SERINE-THREONINE KINASES;

EID: 84877057467     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062012     Document Type: Article

References (55)

1. Rhodes CJ, (2005) Type 2 diabetes-a matter of beta-cell life and death? Science 307: 380-384.
2. Butler PC, Meier JJ, Butler AE, Bhushan A, (2007) The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab 3: 758-768.
3. Bar Y, Russ HA, Knoller S, Ouziel-Yahalom L, Efrat S, (2008) HES-1 is involved in adaptation of adult human beta-cells to proliferation in vitro. Diabetes 57: 2413-2420.
4. Efrat S, (2008) Ex-vivo expansion of adult human pancreatic beta-cells. Rev Diabet Stud 5: 116-122.
5. Parnaud G, Bosco D, Berney T, Pattou F, Kerr-Conte J, et al. (2008) Proliferation of sorted human and rat beta cells. Diabetologia 51: 91-100.
6. Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC, et al. (2005) Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells. J Biol Chem 280: 2282-2293.
7. Liu H, Remedi MS, Pappan KL, Kwon G, Rohatgi N, et al. (2009) Glycogen synthase kinase-3 and mammalian target of rapamycin pathways contribute to DNA synthesis, cell cycle progression, and proliferation in human islets. Diabetes 58: 663-672.
8. Rohatgi N, Remedi MS, Kwon G, Pappan KL, Marshall CA, et al. (2010) Therapeutic strategies to increase human β-cell growth and proliferation by regulating mTOR and GSK-3/β-catenin pathways. Open Endocrinol J. 4: 40-54.
9. Liu Y, Mziaut H, Ivanova A, Solimena M, (2009) Beta-cells at the crossroads: choosing between insulin granule production and proliferation. Diabetes Obes Metab 11: 54-64.
10. Marshak S, Leibowitz G, Bertuzzi F, Socci C, Kaiser N, et al. (1999) Impaired β-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes 48: 1230-1236.
11. Buteau J, Shlien A, Foisy S, Accili D, (2007) Metabolic diapause in pancreatic beta-cells expressing a gain-of-function mutant of the forkhead protein Foxo1. J Biol Chem 282: 287-93.
12. Wajchenberg BL, (2007) Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28: 187-218.
13. Leahy JL, (2009) Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis. Curr Diab Rep 9: 215-20.
14. Negi S, Park SH, Jetha A, Aikin R, Tremblay M, et al. (2011) Evidence of endoplasmic reticulum stress mediating cell death in transplanted human islets. Cell Transplant 21: 889-890.
15. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, et al. (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335: 1638-1643.
16. Kwon G, Marshall CA, Liu H, Pappan KL, Remedi MS, et al. (2006) Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent islets. J Biol Chem 281: 3261-3267.
17. Kawai M, Rosen CJ, (2010) PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol 6: 629-636.
18. Campbell IW, Mariz S, (2007) Beta-cell preservation with thiazolidinediones. Diabetes Res Clin Pract 76: 163-176.
19. Semenkovich CF, (2005) TZDs and diabetes: testing the waters. Nat Med 11: 822-824.
20. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. New England Journal of Medicine 357: 28-38.
21. Leonardini A, Laviola L, Perrini S, Natalicchio A, Giorgino F (2009) Cross-Talk between PPARgamma and Insulin Signaling and Modulation of Insulin Sensitivity. PPAR Res. 1-12.
22. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, et al. (2004) Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53: 1052-1059.
23. Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, et al. (2004) Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 286: E252-E260.
24. Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, et al. (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 70: 177-188.
25. LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, et al. (2006) Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 291: E175-E181.
26. Gleason CE, Lu D, Witters LA, Newgard CB, Birnbaum MJ, (2007) The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. J Biol Chem 282: 10341-10351.
27. Chen Z, Vigueira PA, Chambers KT, Hall AM, Mitra MS, et al. (2012) Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem 287: 23537-23548.
28. Bolten CW, Blanner PM, McDonald WG, Staten NR, Mazzarella RA, et al. (2007) Insulin sensitizing pharmacology of thiazolodinediones correlates with mitochondrial gene expression rather than activation of PPARγ. Gene Regulation and System Biol 1: 73-82.
29. Cersosimo E, Xu X, Musi N, (2012) Potential role of insulin signaling on vascular smooth muscle cell migration, proliferation, and inflammation pathways. Am J Physiol Cell Physiol 302: C652-657.
30. Watson ML, Macrae K, Marley AE, Hundal HS, (2011) Chronic effects of palmitate overload on nutrient-induced insulin secretion and autocrine signalling in pancreatic MIN6 beta cells. PLoS One 6: e25975.
31. Wicksteed B, Alarcon C, Briaud I, Lingohr MK, Rhodes CJ, (2003) Glucose-induced translational control of proinsulin biosynthesis is proportional to preproinsulin mRNA levels in islet beta-cells but not regulated via a positive feedback of secreted insulin. J Biol Chem 278: 42080-42090.
32. Desouza CV, Gerety M, Hamel FG, (2009) Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells. Vascul Pharmacol 51: 162-168.
33. Colca JR, VanderLugt JT, Adams WJ, Shashlo A, McDonald WG, et al. (2013) Clinical proof of concept with MSDC-0160, a prototype mTOT modulating insulin sensitizer. Clin Pharmacol Ther. doi:10.1038/clpt.2013.10.
34. Talchai C, Xuan S, Lin HV, Sussel L, Accili D, (2012) Pancreatic β-cell dedifferentiation as a mechanism of diabetic β-cell failure. Cell 150: 1223-1234.
35. Gurevitch D, Boura-Halfon S, Isaac R, Shahaf G, Alberstein M, et al. (2010) Elimination of negative feedback control mechanisms along the insulin signaling pathway improves beta-cell function under stress. Diabetes 59: 2188-2197.
36. Johnson JD, Bernal-Mizrachi E, Alejandro EU, Han Z, Kalynyak TB, et al. (2006) Insulin protects islets from apoptosis via Pdx1 and specific changes in the human islet proteome. Proc Natl Acad Sci U S A 103: 19575-19580.
37. Szabat M, Luciani DS, Piret JM, Johnson JD, (2009) Maturation of adult beta-cells revealed using a Pdx1/insulin dual-reporter lentivirus. Endocrinology 150: 1627-1635.
38. Wu H, MacFarlane WM, Tadayyon M, Arch JR, James RF, et al. (1999) Insulin stimulates pancreatic-duodenal homoeobox factor-1 (PDX1) DNA-binding activity and insulin promoter activity in pancreatic beta cells. Biochem J 344: 813-818.
39. Szabat M, Kalynyak TB, Lim GE, Chu KY, Yang YH, et al. (2011) Musashi expression in β-cells coordinates insulin expression, apoptosis and proliferation in response to endoplasmic reticulum stress in diabetes. Cell Death and Disease 2: e232.
40. Lechner A, Nolan AL, Blacken RA, Habener JF, (2005) Redifferentiation of insulin-secreting cells after in vitro expansion of adult human pancreatic islet tissue. Biochem Biophys Res Commun 327: 581-588.
41. Ouziel-Yahalom L, Zalzman M, Anker-Kitai L, Knoller S, Bar Y, et al. (2006) Expansion and redifferentiation of adult human pancreatic islet cells. Biochem Biophys Res Commun 341: 291-298.
42. Hanley SC, Pilotte A, Massie B, Rosenberg L, (2008) Cellular origins of adult human islet in vitro dedifferentiation. Lab Invest 88: 761-772.
43. Segrelles C, Moral M, Lara MF, Ruiz S, Santos M, et al. (2006) Molecular determinants of Akt-induced keratinocyte transformation. Oncogene 25: 1174-1185.
44. Patel P, Sekiguchi Y, Oh KH, Patterson SE, Kolb MRJ, et al. (2010) Smad3-dependent and -independent pathways are involved in peritoneal membrane injury. Kidney Intl 77: 319-328.
45. Gunton JE, Delhanty PJ, Takahashi S, Baxter RC, (2003) Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab 88: 1323-1332.
46. Shaw RJ, (2009) LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol 196: 65-80.
47. Fryer LG, Parbu-Patel A, Carling D, (2002) The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277: 25226-25232.
48. Ouyang J, Parakhia RA, Ochs RS, (2011) Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 286: 1-11.
49. Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, et al. (2002) Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110 beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 51: 443-448.
50. Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, et al. (2002) Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 51: 30-36.
51. McDonald WG, Cavey GS, Cole SL, Holewa DD, Brightwell-Conrad AS, et al. (2012) Identification of a mitochondrial target of thiazolidinedione (mTOT). Diabetes 61(Suppl 1): 1096.
52. Bricker DK, Taylor EB, Schell JC, Orsak T, Boutron A, et al. (2012) A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, drosophila, and humans. Science 337: 96-100.
53. Herzig S, Raemy E, Montessuit S, Veuthey JL, Zamboni N, et al. (2012) Identification and functional expression of the mitochondrial pyruvate carrier. Science 337: 93-96.
54. Divakaruni AS, Murphy AN, (2012) Cell biology. A mitochondrial mystery, solved. Science 337: 41-3.
55. Colca JR, McDonald WG, Cavey GS, Cole SL (2013) Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One. In press.